ArticleEuropean journal of breast health2026
Predictive Value of CT-Derived Skeletal Muscle Metrics for Pathologic Complete Response in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.
Article in European journal of breast health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the predictive value of computed tomography (CT)-derived body composition parameters for pathological complete response (pCR) in breast cancer patients receiving neoadjuvant chemotherapy (NAC). Materials and Methods: Female patients who received NAC between January 2010 and December 2022 were retrospectively evaluated. Skeletal muscle index (SMI) and muscle density [mean Hounsfield unit (HU)] were measured at the L3 vertebral level on pretreatment CT. Clinicopathological variables, including molecular subtype, histological grade, and clinical stage, were recorded. Treatment response was categorized as pCR or non-pCR. Univariate and multivariate logistic regression analyses were performed to identify independent predictors of pCR. Receiver operating characteristic (ROC) analysis was used to assess the predictive performance of SMI and HU. Results: A total of 365 patients (mean age, 50.2±11.79 years) were included, and pCR was achieved in 27.9% of cases. Molecular subtype was the strongest independent predictor of treatment response, with the highest pCR rates observed in HER2-positive tumors and the lowest in luminal tumors. Histological grade was associated with pCR in univariate analysis but lost significance in multivariate analysis. Neither SMI nor HU independently predicted pCR. Additional analyses according to molecular subtype demonstrated no significant associations between SMI, HU, and treatment response in luminal, HER2-positive, or triple-negative breast cancer subgroups. ROC analyses showed poor discriminatory performance of both parameters in the overall cohort and subtype-specific analyses (area under the curve range, 0.477-0.565). Conclusion: Molecular subtype remains the primary predictor of treatment response following NAC. In contrast, CT-derived SMI and muscle density showed no predictive value for pCR in either the overall cohort or molecular subtype-specific analyses, suggesting that tumor biology plays a more dominant role than body composition in determining treatment response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.